Foghorn Therapeutics INC

Foghorn Therapeutics stockholders re-elected directors and ratified the appointment of Deloitte & Touche LLP at the 2026 Annual Meeting.

Foghorn Therapeutics announced its first-quarter 2026 financial results and provided an update on its clinical and preclinical programs, highlighting progress in its FHD-909 collaboration with Lilly and advancements in its degrader programs.

Foghorn Therapeutics announced new preclinical data for its FHD-909 inhibitor and degrader programs targeting CBP, EP300, and ARID1B at the 2026 AACR Annual Meeting.

Foghorn Therapeutics Inc. announced the appointment of Ryan D. Maynard, a seasoned biopharmaceutical executive, as its new Chief Financial Officer, effective immediately.

Foghorn Therapeutics announced a $50 million equity financing at a 30% premium and provided positive updates on its oncology pipeline programs.

Foghorn Therapeutics Inc. announced the appointment of Jeff Sacher as interim Chief Financial Officer and Treasurer, effective immediately.

Foghorn Therapeutics reports Q1 2026 results with increased cash reserves, reduced operating expenses, and ongoing development in its oncology pipeline.

Foghorn Therapeutics Inc. reported a reduced net loss for the nine months ended September 30, 2025, driven by decreased operating expenses and continued progress in its collaboration with Eli Lilly and Company.

Foghorn Therapeutics Inc. reported a reduced net loss and lower operating expenses for the first half of 2025, driven by strategic program adjustments and continued collaboration with Eli Lilly and Company.

Foghorn Therapeutics' Q1 2025 shows increased collaboration revenue driven by progress in the Lilly partnership, despite ongoing operating losses.

Foghorn Therapeutics reported a net loss of $19.1 million for the third quarter of 2024, with collaboration revenue decreasing due to the termination of the Merck agreement, offset by increased revenue from the Lilly collaboration.

Foghorn Therapeutics reported its second quarter 2024 financial results, highlighting a recent capital raise and ongoing clinical development programs.

Foghorn Therapeutics' 2024 10-K filing highlights clinical progress with FHD-909, pipeline expansion targeting chromatin regulatory system, and strategic collaboration with Eli Lilly.

Foghorn Therapeutics Inc.'s 2023 10-K filing details its financial status, pipeline advancements, and strategic collaboration with Lilly, emphasizing its focus on chromatin regulatory system therapeutics.

Thomas J. Lynch Jr., a Director at Foghorn Therapeutics Inc., has acquired stock options granting the right to purchase 28,000 shares.

Stuart Duty, a Director at Foghorn Therapeutics Inc., reported the acquisition of 28,000 stock options with an exercise price of $4.08.

Director Scott Biller of Foghorn Therapeutics Inc. was granted stock options for 28,000 shares.

Neil Gallagher, a Director at Foghorn Therapeutics Inc., reported the acquisition of 28,000 stock options with an exercise price of $4.08.

Michael Mendelsohn, a Director at Foghorn Therapeutics Inc., reported the acquisition of stock options.

Ian F. Smith, a Director at Foghorn Therapeutics Inc., reported the acquisition of stock options on June 24, 2026, as per SEC Form 4 filing.

Foghorn Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 24, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Foghorn Therapeutics Inc. will hold its annual meeting of stockholders on June 17, 2025, to elect directors and ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm.

Foghorn Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to vote on the election of directors and ratification of the company's independent accounting firm.

Foghorn Therapeutics will hold its annual stockholders meeting on June 26, 2024, to elect directors and ratify the selection of its independent auditor.

Foghorn Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 26, 2024, to elect directors and ratify the selection of its independent accounting firm.

Flagship Pioneering and its affiliates increased their beneficial ownership in Foghorn Therapeutics Inc. to 27.2% following a $50 million registered direct offering of common stock and warrants.

Deerfield Management and associated entities have filed a Schedule 13G reporting an 8.64% beneficial ownership stake in Foghorn Therapeutics Inc.

FMR LLC and Abigail P. Johnson report beneficial ownership of 11.6% of Foghorn Therapeutics Inc. common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have reported a continued beneficial ownership of 10.2% of Foghorn Therapeutics Inc.'s common stock as of December 31, 2024, through a Schedule 13G Amendment No. 5 filing.